(Q45711101)

15 December 2017

title

BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus (English)

1 reference

15 December 2017

BHIVA Guidelines: coinfection with HIV and Chronic hepatitis B virus (English)

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

14 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

14 March 2024

2

R. Gilson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511247

14 March 2024

author name string

British HIV Association

4

1 reference

15 December 2017

M. G. Brook

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511247

14 March 2024

E. L. Wilkins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511247

14 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14511247

14 March 2024

publication date

1 October 2003

1 reference

full work available at URL

15 December 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1468-1293.4.s1.1.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14511247

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1468-1293.4.s1.1.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1468-1293.4.s1.1.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

14 March 2024

1 reference

15 December 2017

volume

4 Suppl 1

1 reference

15 December 2017

page(s)

42-51

1 reference

Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission.

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Fatal liver failure in haemophiliacs with HIV-induced immunodeficiency: observation of six patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Treatment of chronic hepatitis B: case selection and duration of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Clinical utility in quantifying serum HBV DNA levels using PCR assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.4.S1.1.X

Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS.

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women

14 March 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Hepatitis B and C infections, human immunodeficiency virus and other sexually transmitted infections among women of childbearing age in Côte d'Ivoire, West Africa

14 March 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

[Chronic hepatitis B and C in HIV-infected patients]

14 March 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

14 March 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

14 March 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study

14 March 2024

17

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Are booster immunisations needed for lifelong hepatitis B immunity?

14 March 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Serum HBV-DNA levels in inactive hepatitis B virus carriers.

14 March 2024

31

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

14 March 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

14 March 2024

38

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

14 March 2024

42

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

14 March 2024

45

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

14 March 2024

50

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

14 March 2024

51

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

14 March 2024

58

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

14 March 2024

68

1 reference

https://api.crossref.org/works/10.1046/J.1468-1293.4.S1.1.X

14 March 2024

Identifiers

1 reference

15 December 2017

1 reference